Physician profile
Jonathan Snead
NPI 1821112707
$3,240.71
in general payments reported to CMS, 2019-2025
30 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $68.18 · 2021: $286 · 2022: $1,400 · 2023: $542 · 2024: $393 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $782.47 | 2019-2024 | Lo Loestrin Fe, Liletta, Orilissa |
| Coopersurgical, INC. | $532.43 | 2022 | |
| Mayne Pharma Commercial LLC | $319.61 | 2021-2025 | |
| Astellas Pharma US INC | $231.11 | 2022-2024 | Veozah |
| Exeltis, USA INC. | $195.42 | 2019-2025 | Slynd, Tyblume |
| Shield Therapeutics INC | $156.99 | 2024 | |
| Pfizer INC. | $140.72 | 2022-2024 | |
| Biogen, INC. | $103.36 | 2024-2025 | Zurzuvae, Vumerity |
| Organon LLC | $88.44 | 2021-2025 | Nexplanon |
| Aspira Women'S Health INC | $83.82 | 2022 | |
| Therapeuticsmd, INC. | $77.44 | 2019-2022 | |
| Convatec INC. | $49.62 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $46.25 | 2023 | Myfembree |
| Minerva Surgical, INC | $44.09 | 2019-2023 | |
| Myovant Sciences INC. | $40.94 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $34.14 | 2019-2024 | Novasure |
| Davol INC. | $33.29 | 2025 | Arista |
| Evofem Biosciences, INC. | $30.85 | 2021 | |
| Mylan Pharmaceuticals INC. | $30.66 | 2019 | |
| Avion Pharmaceuticals | $30.16 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $28.73 | 2019 | |
| Smith+Nephew, INC. | $26.18 | 2022 | |
| Daiichi Sankyo INC. | $23.74 | 2022 | |
| Agile Therapeutics, INC. | $21.97 | 2021 | |
| Medicem INC. | $19.60 | 2023 | |
| Merck Sharp & Dohme LLC | $16.98 | 2019 | |
| Myriad Women'S Health, INC. | $15.55 | 2023 | Myrisk |
| Vertical Pharmaceuticals, LLC | $12.86 | 2019 | |
| Channel Medsystems, INC. | $12.13 | 2024 | |
| Allergan, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Snead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.